Browse the evidence

Existing FDA-approved smoking cessation medications (varenicline, nicotine replacement therapy, and bupropion alone) provide only modest attenuation of post-cessation weight gain and do not eliminate it.

Standard smoking cessation drugs like patches, gum, or varenicline will help you quit, but they are not designed to stop you from gaining weight afterward. Expect modest weight changes, but do not rely on them to maintain your weight.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, sotagliflozin) significantly reduce major adverse cardiovascular events (MACE-3), cardiovascular death, and heart failure hospitalizations in patients with type 2 diabetes and established cardiovascular disease, independent of glycemic control.

If you have Type 2 Diabetes and heart disease or heart failure, SGLT2 inhibitors are a first-line treatment option that protects your heart and reduces hospitalization risk, regardless of your blood sugar levels. Consult your doctor about these specific medications.

Bariatric surgery significantly reduces the incidence of mortality and cardiovascular diseases compared to best non-surgical care in patients with obesity.

Bariatric surgery offers a dramatic reduction in mortality and cardiovascular disease risk compared to non-surgical weight loss methods. For patients with obesity, surgery is the most effective intervention for long-term survival and cardiovascular health.

Dysfunctional adipose tissue, particularly visceral fat, drives CKM syndrome by secreting proinflammatory and prooxidative products that damage arterial, cardiac, and kidney tissues, leading to insulin resistance and systemic inflammation.

Excess visceral fat is not just stored energy; it actively releases harmful substances that damage your heart, kidneys, and blood vessels. Managing your weight, specifically reducing visceral fat, is a key medical strategy to reduce inflammation and protect your organs.

Leptin regulates glucose homeostasis through direct actions on POMC neurons, but does not regulate food intake or energy balance through direct actions on these same neurons.

Understanding that leptin's effect on blood sugar is distinct from its effect on hunger helps explain why leptin therapy fails for weight loss in most obese individuals (who are leptin resistant) but might still have metabolic benefits. It shifts focus from 'blocking hunger' to 'metabolic flexibility' and non-POMC pathways.

Acute postexercise elevations in systemic anabolic hormones (testosterone, growth hormone, IGF-1) are neither necessary nor sufficient to stimulate muscle protein synthesis or drive resistance exercise training-induced hypertrophy.

Stop worrying about the exact time of day you train or trying to manipulate your hormones for better gains. Whether you train in the morning or evening, or whether your hormones fluctuate during your menstrual cycle, does not significantly change your ability to build muscle. Focus on consistent, progressive resistance training rather than trying to 'optimize' your hormonal environment.

Obesity is a biologic disorder caused by alterations in CNS pathways controlling energy balance, not a lifestyle failure remediable by willpower alone.

Stop blaming yourself for your weight. Your body is fighting you due to biological mechanisms, not just willpower. Seek medical treatment for obesity just as you would for high blood pressure.

GLP-1 therapy is associated with significant gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) which are dose-dependent and can lead to discontinuation, although most side effects decrease with continued use.

You will likely experience some gastrointestinal side effects like nausea, diarrhea, or constipation, especially when you start the medication or increase the dose. These symptoms often improve over time. Talk to your doctor about managing these side effects through diet and slow dose titration.

Obesity is fundamentally driven by a disruption in energy balance, mediated by central nervous system resistance to leptin and insulin, and dysregulation of the reward system.

Obesity involves biological resistance to satiety signals (leptin/insulin) and reward dysregulation, meaning willpower alone is often insufficient. Medical interventions that bypass or enhance these signals are often necessary.

Obesity is a chronic, progressive, relapsing, and treatable multi-factorial neurobehavioral disease, not just a lifestyle choice.

Understand that obesity is a disease with biological drivers, not just a failure of will. This reduces self-blame and opens the door to effective medical and lifestyle interventions.

SGLT2 inhibitors provide consistent cardiovascular benefits (reduced mortality and morbidity) across all BMI classes in heart failure, with no mediating effect of obesity on their efficacy.

If you have heart failure, SGLT2 inhibitors (like Dapagliflozin or Empagliflozin) are a standard, highly effective treatment that works regardless of your weight. They reduce the risk of hospitalization and death. Discuss starting these with your doctor if you are not already on them.

Genetic variants, particularly in the MC4R, FTO, and LEP/LEPR genes, significantly influence susceptibility to obesity, affecting appetite regulation, energy expenditure, and fat storage.

Genetics play a significant role in obesity risk. If you have a family history of obesity, you may have a higher predisposition. However, this does not mean weight management is impossible; tailored medical and lifestyle strategies can be highly effective.

Higher genetically predicted lifelong BMI causally increases all-cause mortality, with the effect substantially mediated through diabetes.

In this population, higher lifelong BMI significantly increases the risk of premature death, largely by increasing the risk of diabetes. Managing weight and blood sugar are critical for longevity.

Higher genetically predicted BMI causally increases the risk of renal, acute diabetic crisis, and infective deaths.

Higher BMI is strongly linked to death from kidney disease, severe diabetic episodes, and infections. Preventing these outcomes requires addressing underlying metabolic health.

Semaglutide provides robust cardiovascular risk reduction (MACE) in patients with Type 2 Diabetes and established cardiovascular disease, independent of glycemic control improvements.

If you have obesity and established heart disease, semaglutide (2.4mg weekly) significantly reduces your risk of major adverse cardiovascular events (MACE), even if you do not have diabetes. This benefit is driven by weight loss and cardiometabolic improvement, not just blood sugar control.

Obesity drives insulin resistance and type 2 diabetes through the accumulation of free fatty acids and pro-inflammatory cytokines in non-adipose tissues, which activate kinases (PKC, JNK, IKKβ) that inhibit insulin receptor signaling.

If you have obesity, your risk for type 2 diabetes is significantly higher due to biological changes in your fat tissue and blood. This isn't just about 'eating less'; it's about how your body processes energy. Addressing obesity through sustainable lifestyle changes can mitigate these specific biological risks.

High systolic blood pressure (SBP) is a leading metabolic risk factor globally, contributing to 7.8% of total disability-adjusted life-years (DALYs) in 2021, with an increasing annual exposure rate of 1.8%.

High blood pressure is a major driver of global disease burden. Regular monitoring and management are crucial for long-term health.

Persistent hyperglycemia accelerates endogenous AGE formation through the Maillard reaction and dicarbonyl stress, leading to RAGE activation, oxidative stress, and insulin resistance.

Maintaining blood glucose levels within target ranges is critical to preventing the formation of endogenous AGEs and subsequent tissue damage.

Gestational diabetes mellitus (GDM) is the most prominent independent risk factor for the progression to type 2 diabetes in women, increasing the relative risk by approximately 8.3-fold.

If you had gestational diabetes, your risk of developing type 2 diabetes is over 8 times higher than women who did not. This risk persists for years. You need lifelong, regular glucose monitoring and lifestyle interventions, as standard postpartum care often neglects this long-term metabolic risk.

Tirzepatide is associated with a higher incidence of gastrointestinal adverse events (nausea, vomiting, diarrhea) compared to placebo and basal insulin, which can lead to treatment discontinuation.

Tirzepatide often causes stomach problems like nausea, vomiting, and diarrhea, especially at higher doses (10mg and 15mg). These side effects are more common than with placebo or basal insulin and can cause some people to stop taking the medication. Starting at a lower dose and increasing slowly may help.

Peptide 20, a GIPR/GLP-1R/GCGR tri-agonist, achieves balanced potency across all three receptors through specific structural modifications, including lipidation of K10P, which stabilizes binding and enhances receptor-mediated cAMP accumulation.

Peptide 20 is a complex drug that activates three metabolic receptors (GIP, GLP-1, Glucagon) simultaneously. Its effectiveness relies on specific chemical modifications (lipidation) that stabilize the drug's binding to these receptors, leading to significant improvements in blood sugar, weight, and glucose tolerance in animal models.

Leptin signaling via hypothalamic LepRbGlp1r neurons is the primary driver of food intake suppression, as ablating this receptor causes hyperphagic obesity without impairing energy expenditure.

This research identifies a specific brain pathway (LepRbGlp1r neurons) that leptin uses to tell you to stop eating. When this pathway is broken or ignored, you eat more regardless of how much energy you burn. This explains why some obesity treatments focus on mimicking these signals (like GLP-1 drugs) to restore the 'stop eating' signal rather than just forcing exercise.

SGLT2 inhibitors provide significant cardiovascular and renal protection in patients with type 2 diabetes, heart failure, and chronic kidney disease, independent of glycemic control.

If you have Type 2 Diabetes along with heart failure or kidney disease, SGLT2 inhibitors (like Jardiance, Farxiga, or Trulicity's cousin) are now a standard, first-line treatment. They protect your heart and kidneys regardless of your blood sugar numbers. Discuss starting one with your doctor immediately, as guidelines strongly recommend it for this specific patient profile.

Sodium glucose cotransporter 2 inhibitors (SGLT2i) significantly reduce the composite risk of cardiovascular death or heart failure hospitalization in patients with heart failure with preserved ejection fraction (HFpEF), regardless of diabetes status.

If you have HFpEF, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs are proven to reduce the risk of heart failure hospitalization and cardiovascular death, even if you do not have diabetes. They are a standard part of modern treatment.